BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.67 Billion KRW | -62.47% |
| 2022 | 12.44 Billion KRW | -34.83% |
| 2021 | 19.09 Billion KRW | 197.78% |
| 2020 | 6.41 Billion KRW | -24.6% |
| 2019 | 8.5 Billion KRW | 34.19% |
| 2018 | 6.33 Billion KRW | 156.11% |
| 2017 | -11.29 Billion KRW | -275.88% |
| 2016 | -3 Billion KRW | 55.89% |
| 2015 | -6.81 Billion KRW | 0.0% |
| 2013 | -4.06 Billion KRW | 45.34% |
| 2012 | -7.44 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.77 Billion KRW | -660.3% |
| 2024 Q2 | -5.33 Billion KRW | 45.41% |
| 2023 Q1 | 7.06 Billion KRW | 8709.77% |
| 2023 Q2 | 1.36 Billion KRW | -80.74% |
| 2023 FY | 4.67 Billion KRW | -62.47% |
| 2023 Q3 | -5.49 Billion KRW | -504.1% |
| 2023 Q4 | 1.74 Billion KRW | 131.72% |
| 2022 Q4 | -82.04 Million KRW | -101.56% |
| 2022 Q3 | 5.24 Billion KRW | -5.26% |
| 2022 Q2 | 5.53 Billion KRW | 193.79% |
| 2022 FY | 12.44 Billion KRW | -34.83% |
| 2022 Q1 | 1.88 Billion KRW | -52.72% |
| 2021 Q1 | 8.41 Billion KRW | 269.4% |
| 2021 Q2 | 1.74 Billion KRW | -79.24% |
| 2021 Q3 | 4.95 Billion KRW | 183.47% |
| 2021 Q4 | 3.98 Billion KRW | -19.52% |
| 2021 FY | 19.09 Billion KRW | 197.78% |
| 2020 Q2 | 5.63 Billion KRW | 264.21% |
| 2020 Q3 | 4.19 Billion KRW | -25.52% |
| 2020 Q4 | -4.96 Billion KRW | -218.34% |
| 2020 FY | 6.41 Billion KRW | -24.6% |
| 2020 Q1 | 1.54 Billion KRW | -40.31% |
| 2019 Q4 | 2.59 Billion KRW | 53.4% |
| 2019 Q2 | 2.9 Billion KRW | 120.73% |
| 2019 Q1 | 1.31 Billion KRW | -81.66% |
| 2019 FY | 8.5 Billion KRW | 34.19% |
| 2019 Q3 | 1.68 Billion KRW | -41.86% |
| 2018 Q2 | -1.78 Billion KRW | -45.45% |
| 2018 FY | 6.33 Billion KRW | 156.11% |
| 2018 Q4 | 7.18 Billion KRW | 232.02% |
| 2018 Q3 | 2.16 Billion KRW | 221.42% |
| 2018 Q1 | -1.22 Billion KRW | 63.87% |
| 2017 FY | -11.29 Billion KRW | -275.88% |
| 2017 Q3 | -2.93 Billion KRW | 39.89% |
| 2017 Q2 | -4.87 Billion KRW | -1329.13% |
| 2017 Q4 | -3.38 Billion KRW | -15.65% |
| 2017 Q1 | 396.59 Million KRW | 116.19% |
| 2016 Q2 | -411.65 Million KRW | -229.53% |
| 2016 Q3 | -599.69 Million KRW | -45.68% |
| 2016 Q4 | -2.45 Billion KRW | -308.59% |
| 2016 FY | -3 Billion KRW | 55.89% |
| 2016 Q1 | 317.8 Million KRW | 102.77% |
| 2015 Q1 | 581.42 Million KRW | 0.0% |
| 2015 Q4 | -11.47 Billion KRW | -936.09% |
| 2015 FY | -6.81 Billion KRW | 0.0% |
| 2015 Q3 | 1.37 Billion KRW | 491.31% |
| 2015 Q2 | 232.1 Million KRW | -60.08% |
| 2014 Q1 | 147.66 Million KRW | 103.54% |
| 2014 Q2 | 955.88 Million KRW | 547.33% |
| 2014 Q3 | 714.65 Million KRW | -25.24% |
| 2013 Q4 | -4.17 Billion KRW | -4758.7% |
| 2013 Q1 | -822.17 Million KRW | 87.62% |
| 2013 Q3 | -85.93 Million KRW | -108.47% |
| 2013 Q2 | 1.01 Billion KRW | 223.4% |
| 2013 FY | -4.06 Billion KRW | 45.34% |
| 2012 Q3 | -1.43 Billion KRW | 0.0% |
| 2012 Q4 | -6.63 Billion KRW | -362.78% |
| 2012 FY | -7.44 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 102.47% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 148.175% |
| Bioneer Corporation | -10.58 Billion KRW | 144.118% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | 264.414% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 20.021% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 109.547% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 107.288% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 155.398% |
| Medy-Tox Inc. | 9.75 Billion KRW | 52.12% |
| Peptron, Inc. | -15.92 Billion KRW | 129.335% |
| Amicogen, Inc. | -23.28 Billion KRW | 120.056% |
| Genexine, Inc. | -66.87 Billion KRW | 106.984% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | 302.886% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 106.337% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 238.525% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 93.899% |
| SillaJen, Inc. | -20.36 Billion KRW | 122.93% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 66.556% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 124.452% |
| Genomictree Inc. | -8.75 Billion KRW | 153.343% |
| MedPacto, Inc. | -35.32 Billion KRW | 113.222% |
| D&D Pharmatech | 3.93 Billion KRW | -18.734% |
| EASY BIO,Inc. | 15.54 Billion KRW | 69.951% |
| GI Innovation, Inc. | -55.49 Billion KRW | 108.416% |